TD5A Stock Overview
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Tandem Diabetes Care, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$28.36 |
| 52 Week High | US$36.26 |
| 52 Week Low | US$13.24 |
| Beta | 1.13 |
| 1 Month Change | -3.01% |
| 3 Month Change | 36.61% |
| 1 Year Change | -14.73% |
| 3 Year Change | -63.87% |
| 5 Year Change | -49.63% |
| Change since IPO | -76.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| TD5A | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -4.7% | -5.0% | -2.0% |
| 1Y | -14.7% | -13.6% | -0.3% |
Return vs Industry: TD5A underperformed the German Medical Equipment industry which returned -13.6% over the past year.
Return vs Market: TD5A underperformed the German Market which returned -0.3% over the past year.
Price Volatility
| TD5A volatility | |
|---|---|
| TD5A Average Weekly Movement | 9.5% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: TD5A's share price has been volatile over the past 3 months.
Volatility Over Time: TD5A's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 2,400 | John Sheridan | www.tandemdiabetes.com |
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company’s flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user’s body.
Tandem Diabetes Care, Inc. Fundamentals Summary
| TD5A fundamental statistics | |
|---|---|
| Market cap | €1.92b |
| Earnings (TTM) | -€208.90m |
| Revenue (TTM) | €701.66m |
2.7x
P/S Ratio-9.2x
P/E RatioIs TD5A overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TD5A income statement (TTM) | |
|---|---|
| Revenue | US$747.72m |
| Cost of Revenue | US$380.03m |
| Gross Profit | US$367.69m |
| Other Expenses | US$590.30m |
| Earnings | -US$222.61m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | -3.45 |
| Gross Margin | 49.18% |
| Net Profit Margin | -29.77% |
| Debt/Equity Ratio | 92.4% |
How did TD5A perform over the long term?
See historical performance and comparison